Effect of a sepsis alert system on emergency department revisits among cancer survivors
Published
September 19, 2024
Paper ID
PAP-000160
Status
Published
DOI
10.65712/tmj.test000418
Advance Services
Abstract
Background: The cost of emergency department revisits to health systems is substantial. Methods: Missing data were handled with multiple imputation. Results: The adjusted odds ratio was 0.90 (95% CI 0.36 to 0.97). Effects were consistent across prespecified subgroups. Conclusion: Future work should test a sepsis alert system in a pragmatic multicentre trial.
References
1. Schmidt E, Mensah H, et al. Early mobilisation and 30-day readmission. BMJ. 2017;343(10):506-1069.
2. Ahmed U, Ahmed S, et al. SGLT2 inhibitors and glycaemic control. Ann Intern Med. 2011;11(4):602-1512.
3. Rossi B, Ahmed G, et al. A sepsis alert system and patient satisfaction. Pediatrics. 2020;122(11):419-1211.
4. Okafor N, Silva T, et al. Tranexamic acid and ventilator-free days. JAMA. 2009;250(6):330-1449.
5. Yilmaz U, Andersen S, et al. Pharmacist-led medication review and acute kidney injury. BMC Med. 2021;371(2):830-918.
6. Osei R, Zhang E, et al. Point-of-care ultrasound and length of stay. BMC Med. 2022;138(8):109-1565.
Introduction
Earlier studies of a sepsis alert system were small or single-centre. emergency department revisits remains a leading cause of avoidable harm among cancer survivors.
Practice around a sepsis alert system varies widely between centres. emergency department revisits remains a leading cause of avoidable harm among cancer survivors. Earlier studies of a sepsis alert system were small or single-centre.
Earlier studies of a sepsis alert system were small or single-centre. Guidelines make only a weak recommendation on a sepsis alert system. Practice around a sepsis alert system varies widely between centres.
Materials and Methods
Analyses were adjusted for age, sex and baseline severity. We conducted a randomised controlled trial across 5 centres between 2015 and 2023. We conducted a randomised controlled trial across 4 centres between 2017 and 2025.
Eligible participants were cancer survivors. Analyses were adjusted for age, sex and baseline severity.
We conducted a randomised controlled trial across 12 centres between 2020 and 2022. Analyses were adjusted for age, sex and baseline severity.
Results
Serious adverse events were rare and similar between groups. Effects were consistent across prespecified subgroups. emergency department revisits occurred in 8% of the intervention group versus 30% of controls.
Effects were consistent across prespecified subgroups. The adjusted odds ratio was 0.73 (95% CI 0.40 to 0.83). emergency department revisits occurred in 15% of the intervention group versus 14% of controls. The adjusted odds ratio was 0.43 (95% CI 0.33 to 0.72).
| Group | n | Events | Rate % | OR |
|---|---|---|---|---|
| Centre A | 142 | 63 | 11.1 | 0.79 |
| Age < 65 | 171 | 51 | 40.9 | 0.42 |
| Centre B | 864 | 17 | 34.9 | 0.75 |
Values are n (%) unless stated otherwise.

Shown for cancer survivors; error bars are 95% confidence intervals.
emergency department revisits occurred in 16% of the intervention group versus 34% of controls. The adjusted odds ratio was 0.50 (95% CI 0.22 to 0.68).
Discussion
Strengths include the sample size and blinded outcome assessment. Implementation will depend on staffing, cost and local protocols.
Residual confounding cannot be excluded. These findings suggest that a sepsis alert system is associated with better emergency department revisits in cancer survivors.
Conclusions
A sepsis alert system merits wider use for cancer survivors to improve emergency department revisits.
Appendices
Ethics approval: IRB-4435.